Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner

Hepatology

Volumn 50, Issue 3, 2009, Pages 880-892

  Chanda, Dipanjan ^a   Lee, Chul Ho ^b   Kim, Yong Hoon ^b   Noh, Jung Ran ^b   Kim, Don Kyu ^a   Park, Ji Hoon ^c   Hwang, Jung Hwan ^c   Lee, Mi Ran ^f   Jeong, Kyeong Hoon ^d   Lee, In Kyu ^e   Kweon, Gi Ryang ^c   Shong, Minho ^c   Oh, Goo Taeg ^f   Chiang, John Y L ^g   Choi, Hueng Sik ^a  

^a Chonnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Chungnam National University   (South Korea)

^d Mazence Inc   (South Korea)

^e Kyungpook National University School of Medicine   (South Korea)

^f Ewha Womans University   (South Korea)

^g Northeast Ohio Medical University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENYLATE KINASE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHOLINE; CLOFIBRATE; DACTINOMYCIN; FENOFIBRATE; MESSENGER RNA; METHIONINE; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL HETERODIMER PARTNER PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CELL RECEPTOR; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; DRUG ACTIVITY; FATTY LIVER; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CULTURE; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; VIRUS EXPRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; DRUG POTENTIATION; LIVER CELL CARCINOMA; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINES; MALE; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR ALPHA; PROCETOFEN; PYRIMIDINES; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 70349260288     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23049     Document Type: Article

References (27)

1. Seol W, Choi HS, Moore DD. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 1996;272:1336-1339. (Pubitemid 26199974)
2. Chanda D, Park JH, Choi HS. Molecular basis of endocrine regulation by orphan nuclear receptor small heterodimer partner. Endocr J 2008;55:253-268. (Pubitemid 351670949)
3. Lee YS, Chanda D, Sim J, Park YY, Choi HS. Structure and function of the atypical orphan nuclear receptor small heterodimer partner. Int Rev Cytol 2007;261:117-158. (Pubitemid 46856618)
4. Chanda D, Kim SJ, Lee IK, Shong M, Choi HS. Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression. Am J Physiol Endocrinol Metab 2008;295:E368-E379.
5. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase dependent regulation of the orphan nuclear receptor SHP. Diabetes 2007;57:306-314.
6. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000;106:1441-1443.
7. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005;3:35-45. (Pubitemid 41647113)
8. Targher G, Bertolini L, Scala L, Zenari L, Lippi G, Franchini M, et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007;30:e31-e32. (Pubitemid 46684678)
9. Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber- Beckmann R, et al. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. Blood 2003;101:3042-3048. (Pubitemid 36857993)
10. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;14:444:875-880. (Pubitemid 46028447)
11. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-10745.
12. Zambon A, Cusi K. The role of fenofibrate in clinical practice. Diab Vasc Dis Res 2007;(Suppl 3):S15-S20.
13. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861.
14. Nieuwdorp M, Stroes ES, Kastelein JJ. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes Metab 2007;6:869-878.
15. Hardie DG. The AMP-activated protein kinase pathway: new players up-stream and downstream. J Cell Sci 2004;117:5479-5487.
16. Chen LL, Zhang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vasc Pharmacol 2006;44:309-315.
17. Suh JH, Huang J, Park YY, Seong HA, Kim D, Shong M, et al. Orphan nuclear receptor small heterodimer partner inhibits transforming growth factor-beta signaling by repressing SMAD3 transactivation. J Biol Chem 2006;281:39169-39178.
18. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-664.
19. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. HEPATOLOGY 2004;39:1286-1296.
20. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 2006;341:973-978.
21. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 2007;223:277-287. (Pubitemid 47362220)
22. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-1268. (Pubitemid 36873814)
23. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, et al. Auto-induction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1497. (Pubitemid 20105020)
24. Gyamfi MA, Wan YJ. Mechanisms of resistance of hepatocyte retinoid X receptor a-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis. J Biol Chem 2009;284:9321-9330.
25. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004;127:1497-1512. (Pubitemid 39457775)
26. Imagawa S, Fujii S, Dong J, Furumoto T, Kaneko T, Zaman T, et al. Hepatocyte growth factor regulates E box-dependent plasminogen activator inhibitor type 1 gene expression in HepG2 liver cells. Arterioscler Thromb Vasc Biol 2006;26:2407-2413. (Pubitemid 44465741)
27. Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 2006;17:205-215.